Xenobiotic transporters from both the OATP/Oatp and ABCC/Abcc families are known to be significantly altered during the progression of NASH, leading to significant changes in drug disposition. Here, SLCO1A2 is linked to metabolic dysfunction-associated steatohepatitis.